Vonoprazan, a newer potassium-competitive acid blocker (P-CAB), has more rapid and consistent acid suppression than omeprazole because:

• A Vonoprazan is a prodrug activated by gastric acid like omeprazole but has faster conversion kinetics in the low pH of the secretory canaliculus
• B Vonoprazan directly inhibits carbonic anhydrase in parietal cells, reducing the bicarbonate-CO2 exchange needed for proton secretion
• C Vonoprazan has a longer half-life (12 hours vs. 1 hour for omeprazole), ensuring continuous pump inhibition throughout the dosing interval
• D Vonoprazan competitively and reversibly blocks the potassium-binding site of H+/K+-ATPase without requiring acid activation, and maintains binding because potassium exchange is required for each pumping cycle ✓

Explanation

Proton pump inhibitors (PPIs) like omeprazole are pro-drugs requiring activation by gastric acid (pH <2) to form a sulfonamide that covalently and irreversibly binds the cysteine residue of H+/K+-ATPase. This requires active pumps and means 30–40% of pumps (inactive/resting) escape inhibition, explaining the need for pre-meal dosing and delayed onset. Vonoprazan is a potassium-competitive acid blocker (P-CAB) that directly and reversibly binds the potassium-binding site of H+/K+-ATPase in ionic form — no acid activation needed. Because each pumping cycle requires potassium exchange, vonoprazan's sustained ionic binding provides more complete and consistent suppression from the first dose, and it is effective regardless of meal timing.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.